Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation

Brentuximab vedotin (BV) is the first approved novel agent for salvage treatment of relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT). In this study, a literature‐based analysis was undertaken to assess, via an indirect treatment comparis...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Haematol
Main Authors: Kaloyannidis, Panayotis, Hertzberg, Mark, Webb, Kate, Zomas, Athanasios, Schrover, Rudolf, Hurst, Michael, Jacob, Ian, Nikoglou, Thalia, Connors, Joseph M.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2019
Fag:
Transplantation
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7028067/
https://ncbi.nlm.nih.gov/pubmed/31588564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16201
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker